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To investigate whether baseline optical coherence tomography (OCT) parameters can pre-
dict the treatment frequency of intravitreal ranibizumab (IVR) injections during the first year
in patients with diabetic macular edema (DME) treated with pro re nata (PRN) IVR
injections.
Methods
We retrospectively reviewed 68 eyes of 63 patients with center-involved DME who received
IVR injections for 12 months or longer according to three monthly IVR injections followed by
the PRN dosing. We measured the mean retinal thicknesses in the individual subfields of the
Early Treatment Diabetic Retinopathy Study grid and evaluated the qualitative and quantita-
tive parameters on OCT sectional images. We investigated the relationship between these
OCT parameters at baseline and the number of IVR injections during the 12-month follow-up.
Results
Three loading doses were administered to 10 eyes; four to seven annualized IVR injections
were administered to 34 eyes. The number of eyes that received IVR injections decreased
gradually until month 6 and was almost constant from months 7 to 11. No relationships were
seen between the treatment frequency and baseline systemic factors and the ophthalmic
examination findings. Univariate analyses showed that the number of IVR injections during
the first year was associated with the mean retinal thickness in the individual subfields and
the transverse length of the disrupted external limiting membrane (ELM) and ellipsoid zone
of the photoreceptors. Multivariate analysis showed a significant association with the thick-
ness in the inferior subfield alone. The treatment frequency during the 12-month follow-up
was not correlated with improved visual acuity but was associated with the decrease in the
central subfield thickness and disrupted ELM.
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Conclusion
The retinal thickness in the inferior subfield predicts the treatment frequency during the first
year in eyes with DME treated with PRN IVR injections.
Introduction
Diabetic macular edema (DME), in which the blood-retinal barrier (BRB) is disrupted and
neuroglial function deteriorates, often leads to visual impairment in patients with diabetes [1,
2]. Accumulated evidence in basic science and clinical studies has shown that vascular endo-
thelial growth factor (VEGF) plays a key role in the molecular mechanisms in DME, which has
encouraged ophthalmologists to treat DME with anti-VEGF drugs [3–7]. Two major drugs,
ranibizumab (Lucentis, Novartis Pharma AG, Basel, Switzerland; and Genentech Inc., South
San Francisco, CA, USA) and aflibercept (Eylea, Regeneron Pharmaceuticals, Tarrytown, NY,
USA; and Bayer, Berlin, Germany) have been approved worldwide and are the first-line thera-
peutic strategy for managing DME [8, 9].
Considering the half-lives of these drugs in the vitreous humor, three major regimens, i.e.,
fixed monthly or bimonthly, pro re nata (PRN), and treat-and-extend (TAE), can be applied to
treat DME [7–11]. A few clinical trials of intravitreal ranibizumab (IVR) injections for DME
according to the PRN regimen have reported significant reductions in the treatment frequency
in the second year and thereafter [12, 13]. Intriguingly, anti-VEGF therapy improves the sever-
ity of and retards progression of diabetic retinopathy (DR) and the expansion of the nonper-
fused areas in the macula [14, 15]. These data suggested that anti-VEGF drugs have rapid and
direct effects on the disrupted BRB and exert slow and indirect mechanisms in DME resolution.
Despite the beneficial effects, the adverse effects of anti-VEGF management are rare but
severe, e.g., endophthalmitis and life-threatening atherothrombotic diseases [16]. Clinical trials
have suggested that anti-VEGF therapy guarantees the best improvement in visual acuity
(VA), although the socioeconomic burden persists for patients. Actually, the cost-per-quality-
adjusted life years is much higher than other conventional interventions for DME [17–19].
These issues might encourage clinicians to use the PRN regimen for DME and to optimize
the indications for anti-VEGF therapy using predictors of visual prognosis and treatment fre-
quency [20].
In the current study, we investigated the association of baseline systemic and ocular charac-
teristics with the number of PRN IVR injections administered during the first year (3 + PRN
regimen) to treat DME.
Materials and methods
Participants
We retrospectively reviewed 68 consecutive eyes of 63 patients with center-involved DME
treated with IVR injections for 12 months or longer [21]. Patients with center-involved DME
who visited Kyoto University Hospital from March 2014 to October 2015 as the baseline visit
received three monthly injections followed by the PRN phase (3 + PRN regimen). Several
patients dropped out during the 12-month follow-up because of inconvenience, patient desire
to terminate treatment or change to other therapeutic strategies, drug tachyphylaxis, or addi-
tional treatments, i.e., focal/grid photocoagulation, panretinal photocoagulation, vitrectomy
(for vitreous hemorrhage), or cataract surgery. All research and measurements adhered to the
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tenets of the Declaration of Helsinki. The Ethics Committee of the Kyoto University Graduate
School and Faculty of Medicine approved the study protocol. All participants provided written
informed consent before study enrollment.
Intervention
Ranibizumab (0.5 mg) was administered intravitreally according to the 3 + PRN regimen
described in the Ranibizumab Monotherapy or Combined with Laser versus Laser Monother-
apy for Diabetic Macular Edema (RESTORE) study [8]. After disinfection, ranibizumab was
injected 3.5 mm posterior to the limbus followed by instillation of antibiotics. Three monthly
ranibizumab loading doses were followed by PRN IVR injections. At every monthly visit, the
PRN treatment regimen was applied according to the retreatment criteria of the RESTORE
study [8].
Optical coherence tomography
After measurement of the VA and comprehensive ophthalmic examinations, we acquired sec-
tional and three-dimensional images using spectral-domain optical coherence tomography
(SD-OCT) (Spectralis OCT, Heidelberg Engineering, Heidelberg, Germany) at every monthly
visit. After calibration using the corneal curvature radii and focusing knob, vertical and horizon-
tal sectional images dissecting the fovea were acquired using the cross-hair mode (30 degrees).
Three-dimensional images were obtained according to the following parameters; a 49 line raster
scan (central 20 x 20 degree), automatic real-time mean of 16, and high resolution (512 A-scans/
B-scan). Two-dimensional maps subsequently were constructed using the manufacturer’s soft-
ware. The technology enabled automatic measurement of the mean retinal thicknesses of the
central subfield (CSF) and the individual subfields in the parafovea of the Early Treatment Dia-
betic Retinopathy Study (ETDRS) grid, as described previously [22, 23].
We evaluated qualitatively and quantitatively several OCT parameters at the fovea. Briefly,
we determined the presence or absence of cystoid macular edema (CME) and serous retinal
detachments (SRD) and measured the height of the foveal cystoid spaces or SRD at the pre-
sumed foveal center in eyes with CME or SRD using the caliper tool in the Heidelberg Eye
Explorer software (Heidelberg Engineering) [23]. Vitreomacular traction (VMT) was defined
as the presence of an epiretinal membrane involving the fovea or posterior vitreous membrane
with foveal traction on the vertical and horizontal retinal sections of the SD-OCT images.
Vitreomacular adhesion (VMA) was defined as attachment of the posterior vitreous cortex
according to the modified methods described recently [24]. We evaluated the elevation of the
perifoveal vitreous cortex from the retinal surface along with attachment of the vitreous cortex
at the foveal center on the vertical and horizontal sectional OCT images. Such eyes with or
without VMT were included in the group with VMA in this study.
We measured the transverse length of the disrupted ellipsoid zone of the photoreceptors
(EZ) or external limiting membrane (ELM) on the vertical and horizontal images dissecting the
fovea as reported previously [25]. Briefly, we first excluded the areas where reflectivity signals in
the retinal pigment epithelium were attenuated by medial opacity or hyperreflective lesions in
the inner retinal layers, and the areas with damaged photoreceptors then were quantified. The
status of the EZ lines was divided into three categories, i.e., intact, faint, and disrupted, accord-
ing to the OCT reflectivity. The ELM status was defined as intact or disrupted, because the
reflectivity levels in the ELM were almost constant. We thus quantified the transverse length of
the areas where the EZ or ELM line was disrupted within the central 1 mm on the vertical and
horizontal images using the caliper tool in the Heidelberg Eye Explorer software. The average of
the percentage was used in the subsequent investigations. Disorganization of the inner retinal
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layers also was measured as the transverse length of the central areas where the inner retinal lay-
ers could not be segmented clearly as reported previously [26]. Two independent retinal special-
ists evaluated these OCT parameters. If there was disagreement regarding the qualitative
parameters, a third specialist participated. For the quantitative parameters, the average of the
values obtained by two specialists was applied to further analyses.
Statistical analysis
The results are expressed as the median (interquartile range). The differences between two
groups were evaluated using the Wilcoxon signed-rank test or the Mann-Whitney U-test. Spear-
man’s correlation coefficient was calculated to test the statistical correlation. For the multivari-
ate analysis, we performed multiple regression analysis using a stepwise forward approach (the
mean retinal thicknesses in the CSF and the individual parafoveal subfields [nasal, temporal,
superior, and inferior] and the transverse length of the disrupted ELM and EZ as independent
variables and the number of IVR injections during the 12-month follow-up as a dependent vari-
able). P< 0.05 was considered significant.
Results
Association of baseline characteristics with the number of IVR injections
during the first 12 months
We retrospectively reviewed 68 eyes of 63 patients with center-involved DME who received
PRN IVR injections during the first 12 months. Among 125 eyes that met the eligibility crite-
ria, nine eyes met the exclusion criteria at baseline. Of the remaining 116 eyes, 48 eyes were
lost to follow-up before the 12-month examination. Table 1 shows the baseline systemic and
ocular characteristics.
Table 1. Baseline characteristics.
Parameter
Eyes/patients 68/63
































HbA1c: hemoglobin A1c; logMAR: logarithm of the minimum angle of resolution; NPDR: nonproliferative
diabetic retinopathy; PDR: proliferative diabetic retinopathy; PRP: panretinal photocoagulation.
https://doi.org/10.1371/journal.pone.0175809.t001
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All 68 eyes received PRN IVR injections during the 12-month follow-up; only 10 eyes
received three loading doses alone (Fig 1A). Thirty-four eyes received four to seven annualized
injections, and 24 eyes required eight or more IVR injections. We further investigated the num-
ber of eyes that received IVR injections at individual time points. IVR injections were adminis-
tered to 41 eyes at month 3 and the number of eyes decreased gradually until month 6 (Fig 1B).
The number of eyes that received IVR injections was almost constant from months 7 to 11.
We evaluated the relationship between the baseline characteristics and treatment frequency
of IVR injections during the 12-month follow-up and did not identify any significant associa-
tions with systemic factors or the findings on ophthalmic examination (Table 2).
The investigation using OCT parameters showed a positive association between the CSF
thickness and the number of IVR injections during the first year (ρ = 0.408, p<0.001) (Table 3).
Intriguingly, the treatment frequency also was related to the mean retinal thicknesses in the
individual subfields of the parafovea. Among them, the retinal thickness in the inferior subfield
had the most significant association with the number of IVR (ρ = 0.516, p<0.001) (Table 3).
Several OCT parameters other than the retinal thicknesses also were related to the visual out-
comes after treatment with anti-VEGF drugs for DME, which encouraged us to investigate their
association with the number of injections [27–29]. The number of IVR injections in eyes with
CME or SRD did not differ from the number in eyes without such findings (Table 4). The treat-
ment frequency was related to the height of the foveal cystoid spaces in 54 eyes with CME (ρ =
0.431, p = 0.002) but not to the height of the SRD in 21 eyes (ρ = 0.339, p = 0.130). The disruption
of the ELM line or EZ line, which represents photoreceptor damage, was associated positively
with the number of IVR injections (Table 4). Multivariate analyses showed that the treatment
frequency was related to the retinal thickness in the inferior subfield alone (β = 0.492, p<0.001)
among these baseline characteristics.
Relationship between treatment frequency and functional or
morphologic outcomes
The logMAR VA and CSF thickness improved significantly at 12 months (p<0.001 for both
comparisons) (Tables 1, 3 and 5). The mean retinal thicknesses in the parafovea were also
improved, and there were no differences in the changes of the retinal thicknesses between
Fig 1. The number of IVR injections during the first year. (a) Individual numbers of IVR injections during the 12-month follow-up. (b) IVR
injections at individual time points.
https://doi.org/10.1371/journal.pone.0175809.g001
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individual subfields of the parafovea. There was no association between the number of IVR
injections and the visual outcomes or visual improvement (Table 5). The number of IVR injec-
tions during the first year was unrelated to the CSF thickness per se but to its decrease at
month 12 (ρ = 0.120, p = 0.370 and ρ = 0.328, p = 0.007, respectively) (Table 5). The treatment
frequency also tended to be associated positively with the decrease in the transverse length of
the disrupted EZ or ELM line (ρ = 0.212, p = 0.083 and ρ = 0.287, p = 0.019, respectively)
(Table 5).
Table 2. Relationship between preoperative parameters and the number of IVR injections during the
12-month follow-up.
Baseline parameter Association with number of IVR injections




































logMAR: logarithm of the minimum angle of resolution; NPDR: nonproliferative diabetic retinopathy; PDR:
proliferative diabetic retinopathy; PRP: panretinal photocoagulation.
The p-value indicates Spearman’s correlation coefficient for the association of the number of IVR injections
with age, HbA1c, and logMAR VA. The Mann-Whitney U-test was performed to compare gender, systemic
hypertension, lens status, and previous panretinal photocoagulation.
https://doi.org/10.1371/journal.pone.0175809.t002
Table 3. Association between retinal thickness and number of IVR injections during the 12-month fol-
low-up.
Subfield Thickness Association with number of IVR injections
Fovea 441 μm (402–549) ρ = 0.408, p<0.001
Parafovea
Nasal 408 μm (372–468) ρ = 0.483, p<0.001
Temporal 470 μm (389–549) ρ = 0.382, p = 0.002
Superior 433 μm (389–519) ρ = 0.277, p = 0.023
Inferior 414 μm (362–503) ρ = 0.516, p<0.001
The p-value indicates Spearman’s correlation coefficient for the association between the number of IVR
injections and the mean retinal thicknesses in the individual subfields.
https://doi.org/10.1371/journal.pone.0175809.t003
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Discussion
Anti-VEGF treatment improves both visual function and macular morphology in DME,
whereas the severe complications and socioeconomic burden suggest the need to predict the
treatment frequency on a PRN dosing schedule [8, 16–19]. In the current study, we showed for
Table 4. Relationship between other OCT parameters and the number of IVR injections during the
first year.

































Transverse length of disrupted ELM 0% (0–4.4) ρ = 0.377, p = 0.002
Transverse length of disrupted EZ 9.6% (0–27.2) ρ = 0.262, p = 0.032
DRIL 60.8% (36.8–84.5) ρ = -0.001, p = 0.991
The p-value indicates the Mann-Whitney U-test for the comparison of CME, SRD, VMT, and VMA.
Spearman’s correlation coefficient indicates the association of the number of IVR injections with the
transverse length of the disrupted ELM or EZ and DRIL.
DRIL, disorganization of the inner retinal layers.
https://doi.org/10.1371/journal.pone.0175809.t004
Table 5. Relation between visual outcomes at 12 months and number of IVR injections during the
12-month follow-up.
Parameters at 12 months Relation to number of IVR injections
LogMAR VA 0.155 (0.046–0.301) ρ = 0.004, p = 0.971
VA improvement 0.125 (0.030–0.234) ρ = 0.177, p = 0.146
CSF thickness 314 μm (269–386) ρ = 0.120, p = 0.370
Decrease in CSF thickness 132 μm (54–191) ρ = 0.328, p = 0.007
Nasal thickness 356 μm (338–389) ρ = 0.240, p = 0.049
Decrease in nasal thickness 45 μm (13–94) ρ = 0.420, p<0.001
Temporal thickness 371 μm (341–392) ρ = 0.172, p = 0.162
Decrease in temporal thickness 74 μm (32–180) ρ = 0.323, p = 0.009
Superior thickness 365 μm (344–390) ρ = 0.300, p = 0.013
Decrease in superior thickness 61 μm (22–139) ρ = 0.205, p = 0.102
Inferior thickness 352 μm (333–382) ρ = 0.230, p = 0.059
Decrease in inferior thickness 59 μm (17–126) ρ = 0.522, p<0.001
Transverse length of disrupted EZ 0% (0–9.0) ρ = 0.294, p = 0.016
Decrease in disrupted EZ 4.1% (0–17.2) ρ = 0.212, p = 0.083
Transverse length of disrupted ELM 0% (0–0) ρ = 0.405, p<0.001
Decrease of disrupted ELM 0% (0–0) ρ = 0.287, p = 0.019
The p value indicates the Spearman’s correlation coefficient for the association between the number of IVR
injections and individual parameters.
https://doi.org/10.1371/journal.pone.0175809.t005
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the first time that the number of IVR injections during the first year was associated positively
with the retinal thickness in the inferior subfield of the ETDRS grid in eyes that received IVR
injections according to the 3 + PRN regimen. The data are feasible for use in patient consulta-
tions in the clinic and to reduce the treatment burden of the health care system.
Several clinical trials have reported significant reductions in the treatment frequency with
IVR injections during the second year and afterward in eyes treated with PRN IVR injections
for DME [12, 13]. These publications have suggested that the burden of the anti-VEGF treat-
ment depends substantially on the treatment frequency during the first year and, concomi-
tantly, predicting the treatment frequency during this period is an important issue in anti-
VEGF treatment. The current study showed an association between the baseline retinal thick-
ness and the number of IVR injections during the first year. It might to some extent be consis-
tent with the findings of a recent study that showed that, among several parameters, the
baseline central foveal thickness predicts the number of IVR injections needed during the
PRN open-label extension IVR periods after 3-year monthly IVR injections [20].
In the current study, the participants received IVR injections alone during the 12-month fol-
low-up. The major rescue protocol is macular photocoagulation and might reduce the frequency
of IVR treatment [30]. Other publications have reported fewer injections of anti-VEGF drugs
combined with triamcinolone, despite no differences in the visual outcomes [31]. Although
there were no differences in the treatment frequency between eyes with and without VMT in
the current study, most clinicians believe that VMT often prevents anti-VEGF treatment from
achieving complete resolution of DME [32]. Other publications have reported the efficacy of
IVR injections in vitrectomized eyes, which suggests that vitrectomy followed by anti-VEGF
therapy might be a possible alternative strategy and reduce the treatment frequency in eyes with
both DME and VMT [33, 34].
The association between the retinal thickness and treatment frequency with IVR injections
suggests that the magnitude of vascular hyperpermeability might be related to the need for
more frequent injections and might be consistent with the relationship between fluorescein
leakage and the number of injections in a recent publication [20]. VEGF induces vascular
hyperpermeability via several mechanisms. VEGF increases the paracellular or transcellular
flux in vascular endothelial cells [5, 35] and inhibits pericyte function and disrupts the endothe-
lial-pericyte interaction, which contributes to both angiogenesis and vascular permeability [36].
VEGF-induced expression of intercellular adhesion molecule-1 contributes to leukostasis [37].
Concomitantly, retinal capillaries are occluded transiently, and extravasated inflammatory cells
increase cytokines and vascular permeability [4, 38, 39]. The direct effects of anti-VEGF drugs
on vascular endothelial cells is rapid and transient. In contrast, the indirect mechanisms via neg-
ative regulation of pericyte function, transient capillary nonperfusion, or infiltrated inflamma-
tory cells might be slowly exacerbated or improved and might require prolonged and repeated
administration of anti-VEGF drugs [14, 15, 40, 41].
In the current study, the retinal thickness in the inferior subfield had a more significant
association with the treatment frequency with IVR injections than the CSF thickness. The
baseline height of the foveal cystoid spaces also was correlated with the treatment frequency.
Although the implications of retinal thickening in the inferior subfield in DME remain
unknown, we hypothesized that persistent and prolonged edematous changes might impair
the mechanical integrity, which would allow the extracellular fluid to migrate toward the infe-
rior subfield as a result of gravity. In other words, retinal thickening in the inferior subfield
might represent old DME to some extent. A recent study reported an association between the
height of the foveal cystoid spaces and the retinal thickness in the inferior subfield in DME
[23]. Eyes of CME type often have an enlarged foveal avascular zone, which suggests older
DME [42]. Unfortunately, since most patients in the current study were referred to our
OCT findings and treatment frequency with IVR in DME
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institution, we did not know definitively the duration of diabetes, DR, or DME before the ini-
tial injection. A future study should determine whether persistent DME is associated with
larger foveal cystoid spaces and retinal thickening in the inferior subfield and needs more fre-
quent treatment with ranibizumab.
Univariate analyses showed the association of the treatment frequency with the disrupted
ELM at baseline, although multivariate analysis revealed that the number of IVR injections
was related to the retinal thickness in the inferior subfield alone. Statistical analysis suggested
that the disrupted ELM was a confounding factor, because there was the association between
the retinal thickness and the disrupted ELM (data not shown). It is consistent with the shadow
artifacts that the ELM lines are often disrupted beneath severe retinal edema. In addition, fur-
ther investigation should be planned to elucidate whether the treatment frequency was related
to the photoreceptor status in the individual subfield.
The number of IVR injections was associated with improved retinal thickening and photo-
receptor damage but not with VA improvement at month 12. The absence of an association
between functional and anatomic responses to repeated IVR injections suggested the presence
of other mechanisms in visual impairment than edematous changes, which is consistent with
the modest correlation between CSF thickness and VA reduction reported by the Diabetic Ret-
inopathy Clinical Research Network [43]. In addition, we wonder if we can identify the eyes
with greater VA improvement after fewer IVR injections. Further studies should reveal novel
mechanisms independent of edematous changes as novel therapeutic targets [44].
The current retrospective study with a smaller number of Asian cases had several limita-
tions. Another study should determine if these results are generalizable to longer periods,
other populations, and other regimens, e.g., the TAE regimen and the PRN regimens with dif-
ferent loading doses. Since we excluded patients who received additional treatment in the cur-
rent study, eyes less responsive to anti-VEGF drug might have been omitted from this study.
Anti-VEGF drugs affect vascular cells, and the predictors on fluorescein angiography or OCT
angiography images should be reported in a future study [45].
Conclusions
The current study designated baseline macular thickness as a predictor of the treatment fre-
quency during the first year in eyes that followed PRN IVR injection regimen to treat DME,
suggesting its feasibility in the clinic and regarding socioeconomic issues.
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